Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study by unknown
RESEARCH ARTICLE Open Access
Unexpected arterial wall and cellular
inflammation in patients with rheumatoid
arthritis in remission using biological
therapy: a cross-sectional study
Sophie J. Bernelot Moens1*, Fleur M. van der Valk1, Aart C. Strang1, Jeffrey Kroon2, Loek P. Smits1,
Eva L. Kneepkens3, Hein J. Verberne4, Jaap D. van Buul2, Michael T. Nurmohamed3 and Erik S. G. Stroes1
Abstract
Background: Increasing numbers of patients (up to 40 %) with rheumatoid arthritis (RA) achieve remission, yet it
remains to be elucidated whether this also normalizes their cardiovascular risk. Short-term treatment with TNF
inhibitors lowers arterial wall inflammation, but not to levels of healthy controls. We investigated whether RA
patients in long-term remission are characterized by normalized inflammatory activity of the arterial wall and if this
is dependent on type of medication used (TNF-inhibitor versus nonbiological disease-modifying antirheumatic
drugs (DMARDs)).
Methods: Arterial wall inflammation, bone marrow and splenic activity (index of progenitor cell activity) was
assessed with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in
RA patients in remission (disease activity score (DAS28) <2.6 for >6 months) and healthy controls. We performed ex
vivo characterization of monocytes using flow cytometry and a transendothelial migration assay.
Results: Overall, arterial wall inflammation was comparable in RA patients (n = 23) in long-term remission and
controls (n = 17). However, RA subjects using current anti-TNF therapy (n = 13, disease activity score 1.98[1.8–2.2])
have an almost 1.2-fold higher 18F-FDG uptake in the arterial wall compared to those using DMARDs (but with
previous anti-TNF therapy) (n = 10, disease activity score 2.24[1.3–2.5]), which seemed to be predominantly
explained by longer duration of their rheumatic disease in a multivariate linear regression analysis. This coincided
with increased expression of pro-adhesive (CCR2) and migratory (CD11c, CD18) surface markers on monocytes and
a concomitant increased migratory capacity. Finally, we found increased activity in bone marrow and spleen in RA
patients using anti-TNF therapy compared to those with DMARDs and controls.
Conclusions: A subset of patients with RA in clinical remission have activated monocytes and increased inflammation
in the arterial wall, despite the use of potent TNF blocking therapies. In these subjects, RA disease duration was the
most important contributor to the level of arterial wall inflammation. This increased inflammatory state implies higher
cardiovascular risk in these patients, who thus may require more stringent CV risk management.
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Background
Patients with rheumatoid arthritis (RA) are characterized
by an approximately twofold increase in cardiovascular
disease (CVD) risk [1], which cannot be solely attributed
to traditional CVD risk factors [2]. Thus, attention has
shifted toward a direct pathogenic role of the systemic
inflammatory state in RA. Although up to 40 % of RA
patients will reach clinical (articular) remission following
treatment [3], it remains to be established whether the
increased CVD risk also disappears. Treatment with
methotrexate (MTX) in RA patients resulted in a
marked reduction in the inflammatory activity, in con-
junction with a 21 % lower CVD event rate [4, 5]; yet
mortality remains clearly increased compared to the
general population [6, 7]. Considering the potent anti-
inflammatory effects of immune-modulating biological
therapies [8, 9], and in view of the central role of tumor
necrosis factor (TNF) in atherogenesis [10], the intro-
duction of TNF inhibitors holds the promise of further
reducing this residual CVD burden, although definite
outcomes are at present still controversial [11–13].
Supporting its potential role in reducing CVD, anti-
TNF treatment was shown to have favorable effects on
the arterial wall, with beneficial impact on intima media
thickness (IMT) progression as well as arterial wall
stiffness [14]. Short-term (8 weeks) TNF inhibition also
significantly reduced arterial wall inflammation in pa-
tients with active RA, although it failed to completely
normalize arterial inflammation to levels observed in
control subjects [15]. Whether arterial inflammation can
be further reduced during prolonged remission, with or
without anti-TNF treatment, remains to be established.
In analogy to the central role of activated monocytes
regulating synovial inflammation in RA [16], recent data
substantiated a quite similar role for circulating innate
immune cells driving arterial wall inflammation in ath-
erosclerotic disease [17]. In experimental atherosclerosis
models following an acute coronary event (ACS), in-
creased mobilization of myelopoietic precursors from
the bone marrow elicits inflammation of systemic ath-
erosclerotic lesions, mediated by increased influx of
these newly formed inflammatory monocytes [18]. How-
ever, whether RA-associated cell mobilization/activation
contributes to arterial wall inflammation remains to be
established.
In the present study, we assessed arterial wall in-
flammation in RA patients who were in stable clinical
(articular) remission. Considering the above-mentioned
direct role for TNF in atherosclerosis, we also evaluated
the presence of potential drug-specific effects by cat-
egorizing RA subjects into those with either stable
remission with anti-TNF therapy or stable remission
without anti-TNF therapy (but with disease-modifying
antirheumatic drugs (DMARDs). Moreover, we assessed
monocyte phenotype and function, as well as bone mar-
row and splenic ‘metabolic’ activity (an index of progeni-
tor cell activity) using 18F-fluorodeoxyglucose (18F-FDG)




We performed a controlled cross-sectional cohort study
in subjects with an established diagnosis of RA (based
on the ACR/EULAR classification [19]), in remission
(defined by disease activity score in 28 joints (DAS28)
below 2.6 [20]) for more than 6 months. RA subjects
were compared to healthy controls, matched for age and
sex. Because of ethical constraints concerning radiation
exposure, for the imaging studies, healthy controls were
selected from a contemporaneous study using identical
imaging protocols and performed on the same scanner.
For the ex vivo studies, healthy controls (matched for
age and sex) were recruited through advertisement.
General exclusion criteria were medical history of CVD
and the presence of diabetes. To enable comparison of
different treatments, while minimizing confounding by
indication, all patients were selected based on previous
use of anti-TNF therapy. For patients currently on
DMARDs, criteria for discontinuation of TNF inhibitors
were: at least 6 months of treatment with stable use of
concomitant DMARDs, remission based on DAS28 for
at least 6 months. The study protocol was approved by
the Institutional Review Board of the Academic Medical
Center in Amsterdam. Written informed consent was
obtained from each participant.
Baseline data collection
Fasting basal lipid levels, leukocyte count and diffe-
rentiation, erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) were determined using standard
laboratory procedures. Physical examination, including
blood pressure was performed and medical and family his-
tory was recorded. In the RA subjects, disease severity
was recorded at the time of visit using DAS28-ESR, com-
bining swelling and tenderness in 28 joints, general well-
being of the patient (visual analogue scale) and ESR levels
[21]. Date of disease onset, anti-cyclic citrullinated peptide
(anti-CCP), rheumatoid factor (RF) positivity and medica-
tion use were extracted from medical history.
18F-FDG PET/CT imaging
Fasting subjects underwent 18F-FDG PET/CT imaging on
a PET/CT scanner (Philips, Best, the Netherlands) as pre-
viously described [22]. Imaging was initiated, 90 minutes
post 18F-FDG infusion (250 MBq, 6.8 mCi), with a low-
dose, noncontrast-enhanced CT scan for attenuation
Bernelot Moens et al. Arthritis Research & Therapy  (2016) 18:115 Page 2 of 9
correction and anatomic co-registration, followed by PET
imaging of the thoracic and splenic region.
Images were analyzed with dedicated software (OsiriX,
Geneva, Switzerland; http://www.osirix-viewer.com). 18F-
FDG uptake was assessed in the ascending aorta, bone
marrow and spleen. In each artery five regions of interest
(ROIs) were drawn. Maximum standardized uptake values
(SUVmax) were averaged for each artery, and divided by
the average venous background activity (SUVmean) to
obtain the target-to-background ratio (TBRmax). Three
consecutive segments with the highest uptake were used
to determine the most diseased segment (MDS) [22]. The
SUVmax values in the bone marrow and spleen were deter-
mined as follows; bone marrow activity was calculated as
the average SUVmax of all imaged vertebrae, and splenic
SUVmax was obtained as an average of the SUVmax ob-
tained in axial, sagittal, and coronal planes, as previously
described [23].
Ex vivo monocyte studies
Flow cytometry
Red blood cells were lysed with BD FSCSTM-lysis solu-
tion (BD Biosciences, San Diego, CA, USA). Peripheral
blood mononuclear cell (PBMCs) were incubated with
fluorchrome-labeled antibodies (Additional file 1: Table S1)
for 15 minutes and washed with saline. Samples were
analyzed using an FACSCalibur (Becton Dickinson,
Franklin Lakes, NJ, USA). Delta median fluorescence
intensity (MFI), determined with FlowJo software (version
5.4+; Tree Star, Ashland, OR, USA), was calculated by sub-
tracting isotype MFI from MFI of the marker in the corre-
sponding color.
Transendothelial migration
A transendothelial migration (TEM) assay was per-
formed as described previously [24]. Briefly, after over-
night stimulation with TNF-α (10 ng/ml), monocytes
were added to primary human arterial endothelial cells
(HAEC, Lonza, Baltimore, MD, USA), at a concentration
of 1*106 cells/ml for 30 minutes at 37 °C, 5 % CO2 and
then fixed with 3.7 % formaldehyde (Sigma-Aldrich,
Zwijndrecht, the Netherlands). Images were recorded
with a Zeiss Axiovert 200 microscope (Plan-apochromat
10x/0.45 M27 Zeiss-objective; Carl Zeiss Inc., Jena,
Germany). Transmigrated monocytes were distinguished
from adhered monocytes by their transitions from
bright to dark morphology and quantified using the
cell counter plugin (http://rsbweb.nih.gov/ij/plugins/
cell-counter.html) in the Image-J software (http://rsb.info.
nih.gov/nih-image/).
Statistical analysis
Data were analyzed using Prism version 5.0 (GraphPad
Software, La Jolla, CA, USA) and SPSS version 21.0
(IBM Corp,. Armonk, NY, USA). Data are presented as
mean ± standard deviation (SD), for normally distributed
data or medians with interquartile range [IQR], for
nonnormally distributed data unless stated otherwise.
Depending on distribution all comparisons of subgroups
were performed using Student’s t test or Mann-Whitney
U test, and chi-square tests for categorical variables.
Differences in TBR between the groups were assessed
with a univariate analysis of covariance (ANCOVA) to
account for known cardiovascular risk factors: age, gen-
der and smoking status, and any value that differed at
baseline. Univariate and multivariate linear regression
(with body mass index (BMI), systolic blood pressure,
current smoking and one additional explanatory param-
eter as covariates) was performed to explore the correl-
ation between RA-specific characteristics and arterial wall




For the PET/CT study, 23 consecutive RA patients in clin-
ical remission for at least 6 months were included at the
outpatient clinics of the Academic Medical Center (AMC)
and the Amsterdam Rheumatology and Immunology
Center, and compared to 17 age- and sex-matched healthy
controls. RA subjects had an unfavorable CV risk profile
with more smokers, higher blood pressure and higher BMI.
Although CRP levels were generally low, they were higher
in RA subjects compared to controls (RA: 18[13–30] mg/L
vs control: 13[7–16] mg/L, p = 0.022) (Table 1).
Within the RA subjects, ten patients were currently
using nonbiological DMARDs, after they successfully
discontinued their anti-TNF therapy for more than 6
months, whereas 13 patients used anti-TNF therapy.
Nine out of the 13 patients on anti-TNF treatment had a
previous attempt to discontinue which failed, reaching
remission again only upon re-introduction. Age, BMI
and baseline lipid levels were comparable between
groups. Systolic blood pressure was higher in patients
using TNF inhibition (RA, DMARD: 131 ± 22; RA, TNF
inhibition; 151 ± 20, p <0.05 versus all other groups)
(Table 1). DAS28, CRP, ESR as well as percentage sero-
positive RA were equally distributed between the two
groups, but disease duration and duration until first start
of TNF inhibition was significantly longer in the RA,
TNF-inhibition group. RA-specific parameters and type
of RA medication, as well as concomitant cardiovascular
medication are listed in Table 2.
18F-FDG PET/CT
All parameters were adjusted for cardiovascular risk fac-
tors which differed between groups at baseline: systolic
blood pressure, current smoking and BMI. Overall, RA
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subjects in stable remission had levels of arterial wall
inflammation compared to matched controls (aortic
TBRmax: RA; 2.3 ± 0.5 versus control; 2.1 ± 0.3, adjusted
p = 0.251. Aortic TBRmds: RA; 23 ± 0.5 versus control;
22 ± 0.3 adjusted p = 0.331) (Fig. 1a, b).
Surprisingly, upon further assessment of subgroups,
18F-FDG uptake was significantly higher in RA subjects
using anti-TNF therapy compared with the RA, DMARD
group (with comparable disease activity, CRP and ESR
levels) and control subjects, (aortic TBRmax: RA, TNF
inhibition 2.42 ± 0.54 p = 0.004 versus controls. RA,
DMARD; 2.02 ± 0.16, p = 0.011 versus RA, TNF inhib-
ition and p = 0.107 versus controls. Similar for TBRmds)
(Fig. 1c, d).
To assess which factors accounted for the difference in
TBR, we performed a univariate and multivariate linear
regression using CRP, ESR, DAS28 or disease duration
and disease duration till start of TNF inhibition as re-
sponse variables and TBRmax as the dependent variable.
In the multivariate analyses, each of these predictors was
corrected for the cardiovascular risk factors, which dif-
fered at baseline: BMI, systolic blood pressure (SBP) and
current smoking (of which only smoking correlated to
TBRmax, Additional file 1: Table S2). Disease duration
and duration until start of TNF inhibition correlated
with arterial wall inflammation (and in line, with bio-
logical use, data not shown), which remained significant
after correction for potential confounders (Table 3).
Monocyte phenotype and function
We studied phenotype and function of circulating
monocytes in RA patient subjects (including additional
subjects to the imaging cohort: ten RA patients without
anti-TNF therapy who were compared to 13 RA patients
with anti-TNF therapy and 20 age- and sex-matched
controls. All baseline and RA-specific characteristics
were comparable to the imaging study (Additional file 1:
Table S3 and Table S4). Analysis of surface markers
showed increased expression of CCR2, CD11c and CD18
in RA subjects using anti-TNF therapy versus RA,
DMARD and controls (Fig. 2a). Functionally, in a TEM
Table 1 Clinical characteristics of control subjects and RA patients
Control (n = 17) RA (n = 23) p value RA, DMARD (n = 10) RA, anti-TNF (n = 13) p value
Sex, male/female 7/10 8/15 0.680 3/7 5/8 0.637
Age, years 58 ± 13 58 ± 9 0.894 55 ± 11 60 ± 8 0.193
Body mass index, kg/m2 22 ± 2 26 ± 6 0.005 25 ± 6 26 ± 4 0.368
Smoking, yes/no 0/17 8/23 0.022 3/7 4/13 0.708
SBP, mmHg 127 ± 13 143 ± 23 0.014 131 ± 22 151 ± 20 0.028
DPB, mmHg 78 ± 8 87 ± 15 0.036 83 ± 15 90 ± 14† 0.270
Total cholesterol, mmol/L 5.4 ± 0.9 5.4 ± 0.9 1.000 5.3 ± 0.9 5.4 ± 0.9 0.613
LDL cholesterol, mmol/L 3.3 ± 0.9 3.6 ± 1.1 0.396 3.4 ± 0.8 3.7 ± 1.3 0.284
HDL cholesterol, mmol/L 1.7 ± 0.4 1.5 ± 0.5 0.135 1.6 ± 0.5 1.4 ± 0.4 0.152
Triglycerides, mmol/L 0.66[0.5–1.0] 1.2[0.9–1.8] 0.001 1.1[0.9–1.4] 1.3[0.9–2.1] 0.393
CRP, mg/L 13[7–16] 18[13–30] 0.022 16[12–48] 19[14–30] 0.888
Values are n (%), mean ± SD or median [IQR,] for skewed data
RA rheumatoid arthritis, DMARD disease-modifying antirheumatic drug, TNF tumor necrosis factor, SBP systolic blood pressure, DBP diastolic blood pressure,
LDL low-density lipoprotein, HDL high-density lipoprotein, CRP C-reactive protein






ESR, mm/H 9 [7–21] 6 [6–17] 0.689
Disease activity
score (DAS28)
2.24 [1.3–2.5] 1.98 [1.8–2.2] 1.000
Anti-CCP
positive (%)
7 (70) 8 (61) 0.673
Rheumatoid
factor positive (%)
8 (80) 7 (54) 0.192
Disease duration,
years












- Methotrexate 9 11
- Sulfasalazine 1
Other Rx
- Statin 1 1 0.848
- Antihypertensive 5 5 0.580
Values are n (%), mean ± SD or median [IQR,] for skewed data
RA rheumatoid activity, DMARD disease-modifying antirheumatic drug, TNF tumor
necrosis factor, ESR erythrocyte sedimentation rate, DAS28 disease activity score
based on 28 joints, CCP cyclic citrullinated peptide
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assay, this resulted in a 1.5-fold increase of monocytes,
which crossed the endothelial layer (transmigrated cells/
mm2: controls 36 ± 24; RA, DMARD 41 ± 19 p = ns versus
controls; RA, TNF inhibition 57 ± 17, p = <0.05 versus all
other groups) (Fig. 2b, c).
Bone marrow and splenic metabolic activity in RA
patients
Finally, we sought to investigate whether the increased
presence of promigratory monocytes in RA subjects
using anti-TNF therapy would coincide with increased
18F-FDG uptake in hematopoietic organs. Indeed, stand-
ard uptake values (SUVs) were significantly higher in RA
patients using anti-TNF therapy in both bone marrow
(BM) and spleen (BM SUVmax: control 2.44 ± 0.27; RA,
DMARD 2.42 ± 0.24, p = 0.890 versus controls; RA, TNF
inhibition 2.86 ± 0.66, p <0.05 versus all other groups.
Splenic SUVmax: control 2.16 ± 0.45; RA, DMARD
2.20 ± 0.21, p = 0.817 versus controls; RA, TNF in-
hibition 2.65 ± 0.48, p = 0.01 versus all other groups)
(Fig. 3).
Discussion
In the present study, we show that, overall, RA subjects
in long-term clinical remission do not have increased
arterial wall inflammation compared to age- and sex-
matched controls. However, contrary to the expecta-
tions, we observed a markedly increased inflammatory
activity in the arterial wall, combined with an activated,
promigratory phenotype of circulating monocytes in RA
patients using anti-TNF therapy to maintain clinical
remission, compared to RA patients using DMARDs, as
well as age- and sex-matched healthy control subjects.
The concomitantly increased 18F-FDG activity in hema-
topoietic organs (bone marrow and spleen) implies stim-
ulated myelopoiesis contributing to the propagation of
the systemic pro-inflammatory state in RA patients in
remission using anti-TNF therapy.
Increased 18F-FDG uptake in the arterial wall is recog-
nized as an independent predictive marker for future














































































































Fig. 1 Increased arterial TBR in RA patients on anti-TNF therapy.
Quantification of the 18F-FDG uptake as the maximum target-to-
background ratio (TBR) (a, c) and TBR in the most diseased section
(MDS) (b, d) in the ascending aorta revealed that RA subjects in
stable remission have levels of arterial wall inflammation comparable
to healthy controls (a, b). However, we found increased uptake in
RA patients with anti-TNF treatment (n = 13) versus RA subjects on
DMARDs (n = 10) and controls (n = 17). p values are adjusted for age,
gender, BMI, current smoking and systolic blood pressure, * = p < 0.05,
** = p < 0.01. DMARD disease-modifying antirheumatic drug, MDS most
diseased segment, RA rheumatoid arthritis, TBR target-to-background
ratio, TNF tumor necrosis factor
Table 3 Unadjusted and adjusted linear regression analysis with TBRmax as the dependent variable
Characteristic Unadjusted analyses Adjusted analysesα
B (95 % CI) p value B (95 % CI) p value
ESR 0.009(−0.029-0.048) 0.602 0.024(−0.021-0.070) 0.256
CRP −0.056(−0.272-0.159) 0.584 −0.075(−0.318-0.168) 0.513
DAS28 0.060(−0.623-0.744) 0.850 0.087(−0.638-0.910) 0.831
Disease duration 0.023(−0.003-0.050) 0.084 0.038(0.002-0.074) 0.040
Disease duration until start of TNF inhibition 0.064(0.015-0.113) 0.015 0.081(0.004-0.158) 0.040
Data are unadjusted coefficient (B) with 95 % confidence intervals (CI)
TBRmax maximum target-to-background ratio, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28 disease activity score based on 28 joints
αAdjusted for BMI, systolic blood pressure and current smoking
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despite the presence of an adverse CV risk profile,
overall, RA subjects in remission had levels of 18F-FDG
uptake comparable to age- and sex-matched controls.
These data support the concept that effective control of
inflammatory disease activity diminishes CV risk in RA
subjects. However, the FDG uptake in the arterial wall
was significantly elevated in RA patients using anti-TNF
therapy, reaching levels previously associated with a
significant increase in CV risk [25], whereas the signal in
patients who used only DMARDs was comparable to
that in age- and sex-matched controls. These data imply
a persistent inflammatory drive in RA patients in need
of continued anti-TNF therapy, despite clinical remis-

















































Fig. 2 Ex vivo monocyte adhesive and migratory properties. Increased expression (represented as fold change of delta median fluorescent
intensity) of monocyte surface markers CCR2, CD11c and CD18 in RA subjects with anti-TNF treatment (n = 20) versus RA patients with DMARDs
(n = 16) and controls (n = 20) (a). Assessment of transendothelial migratory capacity showed a concomitant increase in number of transmigrated
cells (represented as a white arrow in (b)) (c). Data are means + SEM (for each subject, transmigrated cells are calculated of independent counts of
five frames of view). * = p < 0.05, ** = p < 0.01. DMARD disease-modifying antirheumatic drug, MFI median fluorescence intensity, RA rheumatoid















































































Fig. 3 Bone marrow and splenic activity in RA patients. Cross-sectional 18F-FDG PET/CT images representing 18F-FDG uptake (red) in the aorta,
bone marrow (top and bottom) and spleen (bottom) in a RA patient without (a) or with anti-TNF treatment (b). Quantification of maximum standard
uptake values (SUVmax) showed increased activity in both bone marrow (c) and spleen (d) of RA patients with continued anti-TNF treatment versus RA
patients without anti-TNF treatment and controls. * = p < 0.05, ** = p < 0.01. DMARD disease-modifying antirheumatic drug, RA rheumatoid arthritis,
SUV standardized uptake values, TNF tumor necrosis factor
Bernelot Moens et al. Arthritis Research & Therapy  (2016) 18:115 Page 6 of 9
tapering anti-TNF in these patients cannot be advocated
as one could expect increased vessel wall inflammation,
implying an increased CV risk. An obvious challenge for
the future is to identify this subset of patients.
As TNF inhibitors were previously shown to effectively
lower arterial wall inflammation [15], our findings are
most likely explained by inherent differences between
treatment groups. Patients with and without anti-TNF
therapy were selected retrospectively thus, differences
between these groups may reflect heterogeneity in ‘base-
line’ disease severity, despite current clinical remission
with low disease activity, ESR and CRP levels in both
RA groups. To minimize confounding we only included
patients who had previously been treated with TNF in-
hibitors. Moreover, in the group with ongoing anti-TNF
therapy, 9 out of 13 patients had attempted to withdraw
biological therapy, but failed due to clinical reactivation
of articular symptoms (20 out of 20 for the ex vivo stud-
ies). Interestingly, Saleem et al. previously showed that
short duration of disease symptoms is associated with
successful withdrawal of TNF inhibitors [26]. Although
we did not assess duration of active disease in the
present study, total disease duration was longer in sub-
jects who were on current TNF inhibition compared to
the group who remained in remission after withdrawal
of anti-TNF therapy, and moreover, duration of disease
until first start of TNF inhibitors was also significantly
longer. Notably, disease duration has previously been
identified as an independent risk factor for CVD events
[27, 28]. In our study, after correction for multiple con-
founders, disease duration and time until start of TNF
inhibition were the only RA-specific characteristics that
significantly correlated to TBR. These observations lend
support to the concept that cumulative disease burden
in RA may be particularly deleterious [29, 30], illustrat-
ing that its contribution to CVD risk cannot be captured
in single measurement of disease activity. Eventually, a
disease state can be reached where irrevocable changes
in the joint [29, 31] or dysregulation of the immune re-
sponse [26] persists, which may propagate inflammation
in distant organs and cells, such as circulating mono-
cytes, known to be key players in the chronic inflamma-
tory state. Whether early use of biological therapies can
prevent this [32] and thereby normalizing CVD risk, is a
concept that warrants further investigation.
Activation markers of circulating monocytes in plasma
predict the CV-event rate in patients [33]. Here, we
found a significant increase of CCR2, CD11c and CD18
surface expression on monocytes from RA patients using
anti-TNF therapy. Increased expression of CCR2, the re-
ceptor for monocyte chemo-attractant protein-1 (MCP-1)
promotes chemotaxis [34], and murine studies corrobo-
rated that CCR2 is pivotal in the process of plaque for-
mation [35]. The β2 integrin CD11c/CD18 serves as an
adhesive ligand by interacting with endothelial VCAM-1,
is important in monocyte recruitment and contributes to
formation of atherosclerotic plaques [36]. The functional
relevance of the increased activation status of circulating
monocytes in RA patients using anti-TNF therapy was
substantiated by the increased migratory capacity found in
the ex vivo TEM assay. In patients with advanced athero-
sclerotic lesions we previously reported that activated cir-
culating monocytes accumulated more avidly in arterial
wall lesions with increased TBR activity on PET/CT [24].
In the present study, our observation in RA subjects on
maintenance anti-TNF therapy suggests a similar process,
where increased influx of activated plasma monocytes
may contribute to increased arterial wall inflammation.
Altogether, these data show that RA patients requiring
continuation of anti-inflammatory biological treatment
may have persistently increased ‘subclinical’ inflammatory
activity in both the arterial wall and circulating innate
immune cells.
The half-life of circulating monocytes is approximately
1–3 days [37]. This rapid turnover of inflammatory cells
highlights the important role for their production
sources, the hematopoietic tissues, to continuously sup-
ply new immune cells driving (arterial wall) inflamma-
tion. In RA patients on anti-TNF therapy, both bone
marrow and spleen exhibited increased metabolic activ-
ity compared to RA subjects without anti-TNF therapy
as well as matched controls. In patients’ post-acute
coronary syndrome (ACS), bone marrow and splenic
activity were recently found to correlate to arterial wall
inflammation as well as to independently predict future
CV events [23, 38]. Moreover, activity in BM and spleen
correlates to expression of pro-inflammatory markers on
circulating leukocytes [18, 23]. The present study reveals
increased BM as well as splenic activity in RA patients
with clinical quiescent disease under anti-TNF therapy.
This elevated activity is associated with both arterial wall
inflammation as well as cellular activation, substantiating
a multilevel, subclinical, pro-inflammatory phenotype,
which has been previously linked to an increased risk for
CVD events [39].
Potential limitations
We conducted a cross-sectional study, in which several
limitations need to be considered. First, as aforementioned,
confounding by indication may have contributed to our
findings, which we tried to minimize regarding RA-
related features. However, we cannot account com-
pletely for disease severity with the measures provided
in this study. Moreover, the design precludes conclu-
sions on disease course and influences of previous
medication use. Combined with the small study sam-
ples, we thus cannot draw causal conclusions on the
observations made in our study. Traditional
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cardiovascular risk factors are also increased in RA sub-
jects [40], and may be influenced by factors such as dis-
ease severity or treatment [11, 41]. In our study, except
for systolic blood pressure, which was 20 mmHg higher
in RA patients using anti-TNF therapy, traditional CVD
risk factors were equally distributed between both RA
groups. In line with previous studies [15, 42], we found
no correlation between blood pressure and arterial wall
inflammation, suggesting that the contribution of sys-
tolic blood pressure to arterial wall inflammation in RA
subjects is limited. The use of 18F-FDG PET/CT for BM
and splenic activity has not been fully established and
thus interpretation should be done with caution.
Particularly concerning BM, distinction between direct
involvement in RA and metabolic activity leading to
increased production of inflammatory cells cannot be
made, as we did not assess synovial activity of the joint
affected in RA in the present study. Yet, the vertebrae
of the spinal column were used to assess BM activity,
an organ not known to be affected in RA.
Conclusions
We present, for the first time, a study addressing func-
tional arterial wall changes in RA subjects in prolonged
stable clinical remission. Overall, subjects in long-term
remission had levels of arterial wall inflammation com-
pared to age- and sex-matched controls. However, by
using a unique combination of cellular and imaging data,
we show that the subset of patients requiring continu-
ation of anti-TNF therapy to maintain remission of their
joint disease had increased arterial wall and cellular in-
flammation compared to those using DMARDs only. In
these subjects, RA disease duration was the most im-
portant contributor to the level of arterial wall inflam-
mation. This enhanced inflammatory state implies an
increased cardiovascular risk in these patients, notwith-
standing prolonged clinical remission. In view of this
increased CV risk, stringent risk management may be
necessary in this group, with perhaps a role for lower
treatment thresholds. Finally, the increased hematopoietic
activity in these patients also holds a promise for novel
therapeutic strategies aimed at attenuating the inflamma-
tory state by targeting immune cell mobilization from the
bone marrow.
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